azacitidine,venetoclax,sndx-5613,enasidenib
abbvie,servier,syndax pharma,roche
['sndx-5613', 'beat aml', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'venetoclax']
an honor to present our trial in progress on behalf of the beat aml consortium. phase 1b study of aza/ven/sndx-5613 (menin inhibitor) in newly dx older/unfit #aml with mll or npm1 mut. high unmet need that we hope a triplet can make a huge impact #ash22 
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own